B cell M-CLL clones retain selection against replacement mutations in their immunoglobulin gene framework regions

Front Oncol. 2023 Mar 16:13:1115361. doi: 10.3389/fonc.2023.1115361. eCollection 2023.

Abstract

Introduction: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, accounting for 30-40% of all adult leukemias. The dynamics of B-lymphocyte CLL clones with mutated immunoglobulin heavy chain variable region (IgHV) genes in their tumor (M-CLL) can be studied using mutational lineage trees.

Methods: Here, we used lineage tree-based analyses of somatic hypermutation (SHM) and selection in M-CLL clones, comparing the dominant (presumably malignant) clones of 15 CLL patients to their non-dominant (presumably normal) B cell clones, and to those of healthy control repertoires. This type of analysis, which was never previously published in CLL, yielded the following novel insights.

Results: CLL dominant clones undergo - or retain - more replacement mutations that alter amino acid properties such as charge or hydropathy. Although, as expected, CLL dominant clones undergo weaker selection for replacement mutations in the complementarity determining regions (CDRs) and against replacement mutations in the framework regions (FWRs) than non-dominant clones in the same patients or normal B cell clones in healthy controls, they surprisingly retain some of the latter selection in their FWRs. Finally, using machine learning, we show that even the non-dominant clones in CLL patients differ from healthy control clones in various features, most notably their expression of higher fractions of transition mutations.

Discussion: Overall, CLL seems to be characterized by significant loosening - but not a complete loss - of the selection forces operating on B cell clones, and possibly also by changes in SHM mechanisms.

Keywords: B lymphocytes; antibody; chronic lymphocytic leukemia (CLL); high-throughput sequencing (HTS); immunoglobulin (Ig); lineage trees; machine learning (ML); somatic hypermutation (SHM).

Grants and funding

This study was supported by US-Israel Binational Science Foundation (BSF) grant number 20130432 (to RM). The sequencing was funded by Janssen for diagnostic purposes (to MK and OB). HN was supported by a Bar-Ilan University President’s Scholarship.